Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
artemisia vulgaris allergen extract
- Development stage
- Unknown
- Lead developer
- Leti Pharma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Sublingual
01
Overview
Artemisia vulgaris allergen extract, developed by Laboratorios Leti, S.L., is a biological product used for allergen-specific immunotherapy (AIT) in patients with Artemisia vulgaris (mugwort) allergy. The extract is designed to induce immunological tolerance by repeatedly exposing the patient to controlled doses of the allergen, thereby shifting the immune response from a pro-allergic Th2 profile to a more tolerant Th1 or regulatory T-cell (Treg) profile. This shift is characterized by a decrease in allergen-specific IgE levels and an increase in protective IgG4 antibodies and anti-inflammatory cytokines like Interleukin-10. The extract is standardized in Histamine Equivalent Units (HEP) to ensure consistent biological activity and potency, which is critical for the safety and efficacy of desensitization protocols.
- Brand names
- Depigoid
- Other names
- Mugwort allergen extractArtemisia vulgaris pollen extract
02
Targets
IL10 (Interleukin-10)IgE (Immunoglobulin E)
Beyond the preview
Go deeper on artemisia vulgaris allergen extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on artemisia vulgaris allergen extract.